Genmab is shifting from a royalty-led model toward proprietary growth, with EPKINLY driving strong sales gains and late-stage oncology assets offering a path to diversify revenue. The stock looks attractive for investors who can tolerate patent-expiry and pipeline-execution risk.
Genmab AS (GMAB) is a profitable antibody specialist with a growing commercial portfolio, a late-stage oncology pipeline, and a royalty stream anchored by DARZALEX. The investment case rests on a clear transition: H1 2026 revenue reached $2.05B, up 25% year over year, while EPKINLY sales grew 48% to $312M. The counterweight is equally clear. Gross debt was $5.4B at year-end 2025 against $1.7B of cash, and DARZALEX royalties represented 66% of 2025 revenue.
The strongest medium-term argument is commercial execution. Genmab raised 2026 revenue guidance to $4.33B-$4.53B after H1 revenue growth, and adjusted operating profit guidance to $1.07B-$1.39B. EPKINLY is expanding across diffuse large B-cell lymphoma and follicular lymphoma, while Rina-S and petosemtamab provide two late-stage shots at reducing dependence on royalties.
The principal risk is that the market assigns substantial value to pipeline progress before those assets produce commercial revenue. DARZALEX patents in the US expire in 2029, European patents expire in 2031, and Japanese patents begin expiring in 2030. That timing makes the next several years a test of whether EPKINLY, Rina-S, petosemtamab, and other programs can replace royalty exposure.
At a quoted price of $34.36, the shares merit a Buy rating for a moderate-risk investor with a medium-term horizon. The recommendation depends on continued EPKINLY growth, successful late-stage execution, and steady debt reduction. It is not a low-risk income position, despite the current cash generation.
Genmab A/S, founded in 1998 and headquartered in Copenhagen, develops antibody-based medicines for cancer and other diseases. The company profile lists 3,119 employees and identifies GMAB as a Nasdaq-listed healthcare biotechnology company. Its portfolio includes proprietary products such as EPKINLY and TIVDAK, along with partnered medicines incorporating Genmab innovation.
The business combines three economic models. Royalties generate the largest cash stream, partnered products provide commercial participation, and proprietary programs give Genmab more control over future launches. H1 2026 revenue consisted of $1.71B in royalties, $297M in net product sales and collaboration revenue, and $46M in milestones and reimbursement.
Genmab's collaboration network includes AbbVie, Johnson & Johnson, Pfizer, Novartis, Amgen, Bristol Myers Squibb, BioNTech, Novo Nordisk, and others. The arrangement gives Genmab access to global development and commercial infrastructure, but it also leaves the company dependent on partners for several major products.
Royalties remain the financial engine. H1 2026 royalty revenue of $1.71B represented 83% of total revenue. DARZALEX royalties were the largest contributor, while the company also receives royalties tied to products including Kesimpta, RYBREVANT, TECVAYLI, TALVEY, and TEPEZZA.
The proprietary commercial portfolio is gaining weight. EPKINLY and TIVDAK generated combined sales of $396M in H1 2026, up 37% year over year. EPKINLY contributed $312M, while TIVDAK contributed $84M. EPKINLY therefore supplied roughly four-fifths of the proprietary portfolio sales reported for the period.
The development segment includes Rina-S, petosemtamab, acasunlimab, rinatabart sesutecan, and multiple GEN programs. Rina-S is being studied in platinum-resistant ovarian cancer. Petosemtamab is advancing in head and neck cancer and colorectal cancer. These programs create opportunity, but their value remains tied to clinical outcomes, regulatory approvals, and commercial adoption.
The mix is improving, but concentration remains material. Management said approximately half of H1 2026 revenue growth came from DARZALEX, with the other half coming from EPKINLY and the remainder of the portfolio. That is a healthier growth composition than a single-product story, although the royalty base still dominates current economics.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
EPKINLY, marketed as TEPKINLY in some markets, is Genmab's most important proprietary growth asset. It is approved for adult patients with relapsed or refractory DLBCL and follicular lymphoma, and company materials describe it as the only bispecific antibody approved in both indications.
The product's H1 2026 performance was strong. Sales rose 48% year over year to $312M, with quarterly growth of 28%. Genmab reported increases in US new-patient starts and site activations, while the majority of newly activated sites came from community practices.
EPKINLY's commercial advantages include its dual indication label and the removal of a 24-hour hospitalization recommendation for relapsed or refractory DLBCL. More than 90% of key customers were ordering the product for at least two sites, according to management. That ordering pattern provides a concrete sign that use is spreading beyond a narrow group of specialist centers.
The next major value step is earlier-line DLBCL. Genmab expects top-line data from the EPCORE DLBCL-2 study in Q4 2026. The EPCORE DLBCL-4 study already produced a statistically significant improvement in progression-free survival for an epcoritamab combination in relapsed or refractory DLBCL, although management described overall survival as immature.
Genmab's innovation advantage comes from repeated antibody development rather than one isolated discovery. Company materials identify four proprietary technologies, eight approved therapies incorporating Genmab innovation, and approximately 20 products in clinical development incorporating that innovation.
Epcoritamab demonstrates the platform's commercial value. The DLBCL-4 result extended the clinical evidence for epcoritamab-based combinations, and European approval of TEPKINLY plus lenalidomide and rituximab in second-line follicular lymphoma made it the first bispecific-based therapy approved in Europe for that indication, according to management.
Petosemtamab adds a different type of optionality. It is an EGFR and LGR5 bispecific antibody. Management cited preclinical results showing greater activity than cetuximab in RAS/RAF wild-type colorectal cancer models and is initiating Phase 3 studies in first-line and second-line colorectal cancer.
The advantage is reinforced by partnerships with large pharmaceutical companies that can fund development and provide distribution scale. The limitation is that antibody development remains competitive, and a proprietary platform does not remove the clinical, regulatory, or pricing risks attached to individual products.
Genmab is expanding from a royalty-focused biotechnology company into a more active commercial operator. The company is building sales, distribution, and market-access capabilities for EPKINLY and TIVDAK while preparing for possible launches of Rina-S and petosemtamab.
The operating evidence is strongest in EPKINLY's site expansion. Most new US sites activated in H1 2026 were community practices, and more than 90% of key customers ordered for two or more sites. TIVDAK also recorded expanding site activations, and Genmab secured UK reimbursement through NICE.
The 2025 20-F identifies reliance on a limited number of third-party manufacturers and contract research organizations. Genmab also reported 30 active industry-sponsored clinical trials for proprietary products at the end of 2025, including nine Phase 3 trials, before adding further Merus programs. That scale raises the value of execution discipline as much as scientific insight.
Genmab operates in antibody therapeutics, with exposure to hematologic malignancies, cervical cancer, ovarian cancer, head and neck cancer, and colorectal cancer. The company's commercial and pipeline products therefore address several oncology settings rather than a single disease category.
External biotechnology market estimates show a large but definition-sensitive opportunity. Mordor Intelligence estimates a global biotechnology market of $2.42T in 2026 rising to $4.91T in 2032, while Grand View Research estimates a 13.96% growth rate from 2024 through 2030. These figures do not represent Genmab's addressable market directly, but they identify a favorable backdrop for biologics and antibody innovation.
The more relevant market signal is product adoption. EPKINLY's 48% H1 sales growth, TIVDAK's $84M in H1 sales, and the expansion of EPKINLY into community practices show commercial demand in the company's targeted oncology markets. Future growth depends on converting earlier-line approvals and new indications into durable prescribing behavior.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
Genmab's direct customers include oncology practices, hospitals, infusion centers, distributors, and pharmaceutical partners. EPKINLY's move into community practices is important because it expands the treatment setting beyond major academic centers. The fact that more than 90% of key customers ordered for at least two sites supports this broader customer footprint.
The end users are physicians treating adults with B-cell malignancies, advanced cervical cancer, and other solid tumors. For EPKINLY, the DLBCL and follicular lymphoma labels create multiple opportunities within the same customer relationship. For TIVDAK, Genmab reported expanding use in the US, Japan, and Europe.
Payers are a central part of the customer chain. The 20-F identifies pricing and reimbursement approvals as factors that affect commercialization, while Genmab's UK NICE reimbursement for TIVDAK provides a specific example of market-access progress. Revenue therefore depends on clinical value, physician adoption, payer coverage, and partner execution.
Genmab competes with large pharmaceutical companies, specialty biotechnology companies, academic groups, and developers of alternative treatment modalities. The 20-F specifically identifies bispecific antibodies, CAR-T, and RNA-based technologies as competitive areas.
Johnson & Johnson is both a major Genmab partner and a competitive benchmark in hematology and oncology through products such as DARZALEX, RYBREVANT, TECVAYLI, and TALVEY. AbbVie is the commercial partner for EPKINLY, Pfizer is the partner for TIVDAK, and Novartis commercializes Kesimpta, which incorporates Genmab innovation. These relationships create scale but also place Genmab alongside very well-funded commercial organizations.
The competitive pressure is most visible in bispecific antibodies and antibody-drug conjugates. Industry research identifies more than 20 approved ADCs and more than 300 ADC candidates in clinical trials globally, while Nature Reviews reported nine FDA-approved bispecific T-cell engager antibodies as of 2026. Genmab's differentiation must therefore come from clinical outcomes, convenience, indication breadth, and execution.
Genmab's international structure creates exposure to currency movements. The company reports in US dollars and conducts transactions in US dollars, Danish kroner, and euros. The 20-F identifies foreign-exchange risk related to cash deposits, marketable securities, and payables denominated in currencies other than the reporting currency.
The filing also identifies tariffs, trade restrictions, US-China tensions, the Russia-Ukraine conflict, and conflicts in the Middle East as risks to multinational operations. These factors can affect suppliers, collaborators, clinical activity, market access, and financing conditions. Genmab's exposure is operational rather than purely financial because its products and partners span multiple jurisdictions.
Healthcare policy is another macro variable. Genmab's 20-F lists pricing and reimbursement restrictions as risks, while its TIVDAK NICE reimbursement demonstrates how a single payer decision can influence geographic access. For a company shifting toward independent launches, reimbursement execution becomes more important than it was under a primarily royalty-based model.
Gross debt of $5.4B versus $1.7B of cash leaves Genmab with leverage that is manageable but still meaningful as it funds growth and pipeline execution.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →H1 2026 revenue climbed 25% to $2.05B, with $1.71B from royalties and EPKINLY sales up 48% to $312M.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management lifted 2026 revenue guidance to $4.33B-$4.53B and adjusted operating profit guidance to $1.07B-$1.39B after strong first-half execution.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →At a quoted price of $34.36, Genmab trades below our $42 fair value, leaving room for upside if EPKINLY and the pipeline keep delivering.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The $42 fair value sits between the $35 buy level and the $50 sell level, reflecting solid growth with still-material royalty and pipeline risk.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Genmab has moved beyond the profile of a pre-revenue biotechnology company. H1 2026 revenue reached $2.05B, adjusted operating profit reached $656M, and free cash flow was $1.22B on a trailing basis. EPKINLY's $312M of H1 sales gives the company a growing proprietary commercial asset alongside its established royalty base.
The next phase is more demanding. DARZALEX generated 66% of 2025 revenue, debt rose to $5.4B during 2025, and the company must convert Rina-S, petosemtamab, and earlier-line EPKINLY studies into approved commercial products. Management's raised 2026 guidance and five beats in seven quarters support confidence in execution, but the pipeline still carries genuine biotechnology risk.
A Buy rating is justified at $34.36 because the commercial momentum and forward EPS estimates provide a credible path toward $42.00. The position becomes materially more attractive at $28.00 and less compelling above $50.00. For a medium-term investor, debt reduction, EPKINLY adoption, and the scheduled late-stage oncology readouts are the measures that will decide whether Genmab earns more than its current valuation.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
Genmab A/S (GMAB) jumps after updated Phase 2 petosemtamab data in metastatic colorectal cancer boosted confidence in its oncology pipeline. The move came on heavier-than-usual volume and followed recent positive clinical and analyst developments that strengthened the company’s growth outlook.
SK hynix Inc. (SKHY) rises sharply as Korean semiconductor shares rebound, boosted by strong export data, foreign buying, and renewed AI-memory demand. The move is supported by record operating profit and a low valuation, though average volume suggests this was not a confirmed breakout.
Micron Technology, Inc. (MU) climbs sharply as investors pile into AI and memory stocks after CoreWeave’s strong results and raised outlook reignite the data-center trade. The move also reflects Micron’s earnings beat, above-average trading volume, and a volatile rebound following a steep recent selloff.